(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
4 October 2012 (04.10.2012)

WIPO | PCT

(10) International Publication Number
WO 2012/135740 A2

(51) International Patent Classification:
A61K 39/395 (2006.01) *A61P 29/00* (2006.01)
C12N 5/0781 (2010.01) *C07K 16/28* (2006.01)

(21) International Application Number:
PCT/US2012/031648

(22) International Filing Date:
30 March 2012 (30.03.2012)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
61/470,863 1 April 2011 (01.04.2011) US

(71) Applicant *(for all designated States except US)*: **IMMUNOGEN, INC.** [US/US]; 830 Winter Street, Waltham, MA 02451 (US).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **DECKERT, Jutta** [US/US]; 16 Eaton Road, Lexington, MA 02420 (US). **SETIADY, Julianto** [ID/US]; 132 Clocktower Drive, Unit 4110, Waltham, MA 02452 (US). **PARK, Peter U.** [US/US]; 25 Webster Avenue, #301, Somerville, MA 02143 (US).

(74) Agents: **STEFFE, Eric K.** et al.; Sterne Kessler Goldstein Fox P.L.L.C., 1100 New York Avenue N.W., Washington, DC 20005 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.


(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU,

[Continued on next page]

(54) Title: CD37-BINDING MOLECULES AND IMMUNOCONJUGATES THEREOF

(57) Abstract: Methods of using CD37 agents, including, but not limited to, antibodies and immunoconjugates, that bind to CD37 to deplete B-cells (e.g., non-cancerous B-cells) and methods of treating autoimmune and inflammatory diseases are further provided.

Figure 4



WO 2012/135740 A2

LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— *without international search report and to be republished upon receipt of that report (Rule 48.2(g))*

— *with (an) indication(s) in relation to deposited biological material furnished under Rule 13bis separately from the description (Rules 13bis.4(d)(i) and 48.2(a)(viii))*